2026-10-19T00:27:46Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/150522026-10-18T21:14:27Zopenairedrivercom_ebyu_10000col_ebyu_10001

Pharmacomechanical thrombectomy for acute symptomatic lower extremity deep venous thrombosisEyup, Serhat CalikOzgur, DagMehmet, Ali KayginOruc, Alper OnkBilgehan, ErkutzAdultCombined Modality TherapyFemaleHumansLower ExtremityMaleMechanical ThrombolysisMiddle AgedThrombectomyThrombolytic TherapyTreatment OutcomeVenous Thrombosisalteplaseheparinlow molecular weight heparinwarfarinanticoagulant therapyArticlebleedingblood clot lysisblood vessel injuryclinical articleechographyfemoropopliteal vein thrombosisgingiva bleedinghematomahumaniliofemoral thrombosisleg phlebographylower extremity deep vein thrombosisBackground: The purpose of this study was to evaluate the efficacy and safety of pharmacomechanical thrombectomy performed by using a rotational thrombectomy device for the treatment of deep vein thrombosis. Methods: Between April 2012 and November 2014, 17 patients with acute deep vein thrombosis underwent pharmacomechanical thrombolysis. The thrombectomy device was used in a single-session technique for patients with lower-extremity deep vein thrombosis. After the procedure, the effect of thrombolysis was evaluated in 3 grades venographically. Grade I showed lysis of under 50%, and grade III showed complete lysis. Results: Ten patients (58.8%) had an iliofemoral thrombosis and 7 (41.2%) had a femoropopliteal venous thrombosis. At the end of the pharmacomechanical thrombectomy procedure, 12 patients (70%) had complete (grade III) thrombus resolution. Grade I and II lysis were noted in 2 (12%) and 3 (18%) patients, respectively. Additionally, four (23.5%) required an additional lytic infusion as a result of residual thrombi. The overall grade III, II, and I thrombus resolution rates, including the supplemental thrombolysis, were 82.2% (n = 14), 12% (n = 2), and 5.8% (n = 1), respectively. There was no mortality. Conclusion: Based on the present data, use of the Cleaner thrombectomy device may prove to be a safe and feasible single-session pharmacomechanical thrombectomy method for the treatment of acute deep vein thrombosis. To prove the effectiveness of this type treatment, a more extensive largescale studies are needed. © 2015 Forum Multimedia Publishing, LLC.Carden Jennings Publishing Co. Ltd2015Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/15052https://doi.org/10.1532/hsf.13661098-3511enHeart Surgery Foruminfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15052